OBIO
Orchestra BioMed Holdings Inc.
NASDAQ: OBIO · HEALTHCARE · BIOTECHNOLOGY
$3.80
-2.56% today
Updated 2026-04-29
Market cap
$239.94M
P/E ratio
—
P/S ratio
7.17x
EPS (TTM)
$-1.11
Dividend yield
—
52W range
$2 – $5
Volume
0.2M
WallStSmart proprietary scores
37
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A6.5
Quality
B3.5
Profitability
D4.0
Valuation
C3/9
Piotroski F-Score
Weak
-6.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$12.43
+227.11%
12-Month target
—
—
Intrinsic (DCF)
$2.45
Margin of safety
-65.71%
2 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 12,120.00% QoQ
+ Debt/equity 0.04x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -6.21 — distress zone
- Thin margins at -157.40%
- Negative free cash flow $-2.30M
- 65.71% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $3.53M | $2.76M | $2.64M | $33.48M | $33.48M |
| Net income | $-33.61M | $-49.12M | $-61.02M | $-52.95M | $6.25M |
| EPS | — | — | — | — | $-1.11 |
| Free cash flow | $-29.88M | $-46.20M | $-50.85M | $-49.45M | $-2.30M |
| Profit margin | -951.26% | -1,779.71% | -2,313.27% | -158.16% | -157.40% |
Peer comparison
Smart narrative
Orchestra BioMed Holdings Inc. trades at $3.80. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -6.21, it sits in the distress. TTM revenue stands at $33.48M. with profit margins at -157.40%. Our DCF model estimates intrinsic value at $2.45.
Frequently asked questions
What is Orchestra BioMed Holdings Inc.'s stock price?
Orchestra BioMed Holdings Inc. (OBIO) trades at $3.80.
Is Orchestra BioMed Holdings Inc. overvalued?
Smart Value Score 37/100 (Grade D, Sell). DCF value $2.45.
What is the price target of Orchestra BioMed Holdings Inc. (OBIO)?
The analyst target price is $12.43, representing +227.1% upside from the current price of $3.80.
What is the intrinsic value of Orchestra BioMed Holdings Inc. (OBIO)?
Based on our DCF model, intrinsic value is $2.45, a -65.7% margin of safety versus $3.80.
What is Orchestra BioMed Holdings Inc.'s revenue?
TTM revenue is $33.48M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
-6.21 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.17x
ROE-109.40%
Beta0.60
50D MA$4.34
200D MA$3.76
Shares out0.06B
Float0.03B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—